Browsing by Author "Banerjee, Uttam C."

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    2-(2-Arylphenyl) benzoxazole As a Novel Anti-Inflammatory Scaffold: Synthesis and Biological Evaluation
    (ACS publications, 2014) Seth, Kapileswar; Garg, Sanjeev K.; Kumar, Raj; Purohit, Priyank; Meena, Vachan S.; Goyal, Rohit; Banerjee, Uttam C.; Chakraborti, Asit K.
    The 2-(2-arylphenyl)benzoxazole moiety has been found to be a new and selective ligand for the enzyme cyclooxygenase-2 (COX-2). The 2-(2-arylphenyl)benzoxazoles 3a−m have been synthesized by Suzuki reaction of 2-(2-bromophenyl)benzoxazole. Further synthetic manipulation of 3f and 3i led to 3o and 3n, respectively. The compounds 3g, 3n, and 3o selectively inhibited COX-2 with selectivity index of 3n much better than that of the COX-2 selective NSAID celecoxib. The in vivo anti-inflammatory potency of 3g and 3n is comparable to that of celecoxib and the nonselective NSAID diclofenac at two different doses, and 3o showed better potency compared to these clinically used NSAIDs.
  • Thumbnail Image
    Item
    Dual inhibitors of epidermal growth factor receptor and topoisomerase IIa derived from a quinoline scaffold
    (Royal Society of Chemistry, 2016) Chauhan, Monika; Joshi, Gaurav; Kler, Harveen; Kashyap, Archana; Amrutkar, Suyog M.; Sharma, Praveen; Bhilare, Kiran D.; Banerjee, Uttam C.; Singh, Sandeep; Kumar, Raj
    Based on the quinazoline bearing EGFR inhibitors, a series of thirty four compounds having a quinoline scaffold were synthesised and evaluated in vitro for EGFR kinase inhibitory activity. A structure-activity relationship study revealed that 2,4-bis(arylamino) substituted quinolines possessed better anti-EGFR kinase activity. Compounds 3f and 3m emerged as potent EGFR kinase inhibitors (200 and 210 nM, respectively) and showed excellent anticancer activity at the micromolar level against a panel of cancer cell lines comparable to erlotinib. Furthermore, representative compounds inhibited the human topoisomerase II? selectively and catalytically, did not intercalate with DNA, increased intracellular ROS concentration (except 3m) and altered the mitochondrial membrane potential of the cancer cells. Cell cycle analysis and annexin-V staining in a lung cancer cell line showed that the compounds delayed cell cycle progression by inducing cell cycle arrest and subsequent apoptosis at the G1 phase. The facts were further corroborated through molecular modeling studies. ? 2018 The Royal Society of Chemistry.
  • Thumbnail Image
    Item
    Synthesis and biological evaluation of new 2, 5- dimethylthiophene/furan based N-acetyl pyrazolines as selective topoisomerase II inhibitors
    (Royal Society of Chemistry, 2016) Darpan; Joshi, Gaurav; Amrutkar, Suyog M.; Baviskar, Ashish T.; Kler, Harveen; Singh, Sandeep; Banerjee, Uttam C.; Kumar, Raj
    Based on the reported pharmacophores as topoiomerase inhibitors, 2,5 dimethylthiophen/furan based N-acetyl pyrazolines were designed and envisaged as topoisomerase inhibitors. The target compounds were synthesized and tested in vitro against human topoisomerases in decatenation, relaxation, cleavage complex and DNA intercalation assay. Out of 29 compounds, three (10, 11 and 29) showed potent and selective toposiomerse II inhibitory activity with no intercalation with DNA. Further, molecular docking studies also endorsed them as ATP dependent topoisomerase II catalytic inhibitors. These compounds exerted potential anticancer effects on breast, colon, lung and prostate cancer cell lines at low micromolar level as compared to etoposide and low toxicity to normal cells. Apart from the topoisomerase II inhibition, these compounds also induced the reactive oxygen species (ROS) level in cancer cells. The cell cycle analyses showed their apoptotic effect at G1 phase.
  • Thumbnail Image
    Item
    Synthesis of imine-pyrazolopyrimidinones and their mechanistic interventions on anticancer activity
    (2013) Baviskar, Ashish T.; Banerjee, Uttam C.; Gupta, Mukesh; Singh, Rajveer; Kumar, Sunil; Gupta, Manish K.; Kumar, Sanjeev; Rout, Satish K.; Khullar, Madhu; Singh, Sandeep; Kumar, Raj
    Design, synthesis and anticancer activity of a series of imine-pyrazolopyrimidinones is reported for the first time. Compounds 9d, 9n and 9o in the series show encouraging in vitro anticancer activity with low micromolar IC50 values against prostate (PC3) and breast (MCF7) cancer cell lines. Some notions about structure-activity relationships and plausible mechanism of biological activity are presented. ? 2013 Elsevier Ltd. All rights reserved.